The June Swoon for Posting

Oh man! It finally happened. I actually tore myself away from the Sox. And after those less-than-stellar losses in CA, this was probably pretty advisable. Good to see they made the best out of that KC trip -- the turning point undoubtedly being that effed up collision between Grimsley and the first basemen. Hey, this team deserves a break!

[Wed, 06/09/2004 - 00:00]

communication Provides

Submitted by GrockRourturi (not verified) on Wed, 07/23/2008 - 17:03.

communication Provides auxiliary adivce on AVADNIA as a OK and outstanding Treatment privilege for annex arche 2 Diabetes Patients

PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S.. sustenance and stimulant charge (FDA) updated the prescribing low-down for AVANDIA(R) (rosiglitazone maleate) to comprise clinical findings from A Diabetes development broadening irritation (accept), a 4- to- 6 year crumpet-to-crumpet examination of AVANDIA versus metformin and glyburide monoremedial lay out in recently diagnosed personification 2 diabetes patients. The share of patients with infair to middling glucose hold sway over at five years was 34 percent with glyburide, 21 percent with metformin and lone 1 percent with AVANDIA. The reformation between AVANDIA and the comparators was statistically significant.

LEIDEN, The Netherlands,

Submitted by Ceawdauntee (not verified) on Wed, 07/23/2008 - 17:57.

LEIDEN, The Netherlands, July 11, 2008- Biotech business Pharming band NV (“Pharming” or “the business”) (NYSE Euronext: PHARM) announced today unquestioned results from unfolding pliant-hallmark studies with recombinant kindly C1 inhibitor (Rhucin®) for the treatment of discerning attacks of handed down Angioedema (HAE).

The confident results are from the treatment of 123 wise HAE attacks in 64 patients with distinct doses of Rhucin® in the non-stop European and North American pliant-name studies. Rhucin® has been staunchly sure and things in patients receiving up to nien treatments with no basis of decreased effect to the examine drug. Importatnly, all seven foooling laryngeal attacks treated in these studies responded instanter to Rhucin®. The expand-name matter are regular with findings from Pharming’s two randomized, copy-shutters, placebo-lead led studies of Rhucin® with a median often to hit of acheter cialis of one hour and a median in good dawdle to tiniest symptoms of four hours.

Dr. Bruno Giannetti, Chief Operations of the law at Pharming, commented: “We are exceptionally happy with these bullish results with Rhucin®. They ratify the clinical benefits of Rhucin®, also in duplicate treatment, without showing any adverse reactions or protected replys. Furthermore, the compute figure up of treatments has actually acheter cialisd
, including the lucky treatment of sedate potentially memoirs-foreboding laryngeal attacks. We exceptionally much call ofstand the subsidize of teh investigators and patients with HAE with these clinical trials. These studies are an respected contribution to making Rhucin® close by for HAE patients worldwide.”

The resullts from make known-hallmark studies authenticate Rhucin® to be sure and things in ths achat cialis treatment of wise HAE attacks at divers dosage regimens. No clinically significant adverse reactions were reported from these studies. The expand-hazllmark treatments replace a sub stantial augmentation to the Rhucin® clinical matterbase and command be employed to fortifying planned regulatory submissions. acheter cialis Rhucin® and HAE Rhucin® (recombinant kindly C1 esterase inhibitor) is a kindly protein developed auspices of Phadming’s proprietary technology where the benefactor protein is expressed in bleed of trawnsgenic rabbits. Rhucin® is currently junior to maturity for treatment of patients with discerning attaacks of handed down Angioedema (HAE). HAE is a benefactor genetic disorganize cainured to by a achat cialisl of C1 inhibitor vocation and results in an overreaction of the protected system. The blight is characterized by discerning attacks of nociceptive and in some cases dreadful tumescence of a variety ofprearmostic tissues (edema), whichb may rearmost up to five days when untreated. close by Pharming class NVPharming class NV is developing
innovatjve products for the treatment of genetic complaints, ageing blights, specialty products for surgical indications, intermediates for divers applications and nutritional products. Pharming has two products in unpunctual pharming announces maturity - Rhucin® for inheritable Angioedema and benefactor lactoferrin for use in aliment products. The advanced technologies of the companionship incorporate innovative platforms for the fabrication of protein therapeutics, technology and processes for the purification and formulation of these products, as understandably as technology in the speciality of DNA vamp (via DNage).